Clinical Perspectives for F-18-FDG PET Imaging in Pediatric Oncology: Metabolic Tumor Volume and Radiomics

Pediatric cancer, although rare, requires the most optimized treatment approach to obtain high survival rates and minimize serious long-term side effects in early adulthood. F-18-FDG PET/CT is most helpful and widely used in staging, recurrence detection, and response assessment in pediatric oncology. The well-known F-18-FDG PET metabolic indices of metabolic tumor volume (MTV) and tumor lesion glycolysis (TLG) have already revealed an independent significant prognostic value for survival in oncologic patients, although the corresponding cut-off values remain study-dependent and not validated for use in clinical practice. Advanced tumor "radiomic" analysis sheds new light into these indices. Numerous patterns of texture F-18-FDG uptake features can be extracted from segmented PET tumor images due to new powerful computational systems supporting complex "deep learning" algorithms. This high number of "quantitative" tumor imaging data, although not decrypted in their majority and once standardized for the different imaging systems and segmentation methods, could be used for the development of new "clinical" models for specific cancer types and, more interestingly, for specific age groups. In addition, data from novel techniques of tumor genome analysis could reveal new genes as biomarkers for prognosis and/or targeted therapies in childhood malignancies. Therefore, this ever-growing information of "radiogenomics", in which the underlying tumor "genetic profile" could be expressed in the tumor-imaging signature of "radiomics", possibly represents the next model for precision medicine in pediatric cancer management. This paper reviews F-18-FDG PET image segmentation methods as applied to pediatric sarcomas and lymphomas and summarizes reported findings on the values of metabolic and radiomic features in the assessment of these pediatric tumors.